Medium chain unsaturated fatty acid ethyl esters inhibit persister formation of Escherichia coli via antitoxin HipB

Appl Microbiol Biotechnol. 2018 Oct;102(19):8511-8524. doi: 10.1007/s00253-018-9271-3. Epub 2018 Aug 7.

Abstract

Persisters represent a small bacterial population that is dormant and that survives under antibiotic treatment without experiencing genetic adaptation. Persisters are also considered one of the major reasons for recalcitrant chronic bacterial infections. Although several mechanisms of persister formation have been proposed, it is not clear how cells enter the dormant state in the presence of antibiotics or how persister cell formation can be effectively controlled. A fatty acid compound, cis-2-decenoic acid, was reported to decrease persister formation as well as revert the dormant cells to a metabolically active state. We reasoned that some fatty acid compounds may be effective in controlling bacterial persistence because they are known to benefit host immune systems. This study investigated persister cell formation by pathogens that were exposed to nine fatty acid compounds during antibiotic treatment. We found that three medium chain unsaturated fatty acid ethyl esters (ethyl trans-2-decenoate, ethyl trans-2-octenoate, and ethyl cis-4-decenoate) decreased the level of Escherichia coli persister formation up to 110-fold when cells were exposed to ciprofloxacin or ampicillin antibiotics. RNA sequencing analysis and gene deletion persister studies elucidated that these fatty acids inhibit bacterial persistence by regulating antitoxin HipB. A similar persister cell reduction was observed for pathogenic E. coli EDL933, Pseudomonas aeruginosa PAO1, and Serratia marcescens ICU2-4 strains. This study demonstrates that fatty acid ethyl esters can be used to disrupt bacterial dormancy to combat persistent infectious diseases.

Keywords: Ethyl cis-4-decenoate; Ethyl trans-2-decenoate; Ethyl trans-2-octenoate; Fatty acid ethyl esters; Persister cells.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Antitoxins / metabolism*
  • Bacterial Infections / drug therapy
  • Bacterial Infections / metabolism
  • Ciprofloxacin / pharmacology
  • DNA-Binding Proteins / metabolism*
  • Escherichia coli / drug effects*
  • Escherichia coli / metabolism*
  • Escherichia coli Proteins / drug effects*
  • Escherichia coli Proteins / metabolism
  • Esters / pharmacology*
  • Fatty Acids / pharmacology*
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / metabolism
  • Serratia marcescens / drug effects
  • Serratia marcescens / metabolism

Substances

  • Anti-Bacterial Agents
  • Antitoxins
  • DNA-Binding Proteins
  • Escherichia coli Proteins
  • Esters
  • Fatty Acids
  • hipB protein, E coli
  • Ciprofloxacin